VA-REGULA
25.1.2024 08:01:35 CET | Business Wire | Press release
Before adopting an IDV system, it’s imperative to conduct thorough testing, especially for large-scale businesses. However, it is nearly impossible to obtain a reliable set of IDs with real NFC chips (as they contain sensitive personal data) to test-drive the verification process. Besides, it’s not that easy to test both positive and negative verification scenarios without representative ID sampling. Regula’s unique service, Regula NFC TestKit, effectively addresses these issues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240124863941/en/
An example of a test ID made for Regula NFC TestKit service customers (Photo: Business Wire)
Depending on the particular company’s business needs and market goals, Regula creates a test set of identity documents with NFC chips which are personalized with the data of fictitious identities or those provided by the customer. Apart from the chip, a visual zone and a machine readable zone (MRZ) can also be generated to enable robust cross-checking and system testing. These test IDs are simplified images (with special marks to show that they are not full replicas) of the required pages of the documents the company intends to verify. They are backed up with corresponding templates in a special database version so that the IDV solution can recognize them properly.
By choosing Regula NFC TestKit service, enterprises can benefit from:
- Shorter time to market. Checking and fine-tuning the IDV process with the help of test documents eliminates the necessity of undergoing an early adoption period during which a company could face friction.
- Enhanced IDV solution trial and early problem identification. Regula NFC TestKit service provides the most complete representation of identity documents with multiple data fields. That means any organization can test-drive the complete remote onboarding procedure to address potential issues or vulnerabilities.
- Flexibility and customization. Regula’s service is tailored to the specific needs of any given organization. It is possible to create an NFC-chip-based document sample of any type from any country to test the most likely customer onboarding scenarios.
- Maximum security assurance. Using NFC chips and replicating the data in the MRZ and visual zone ensures that IDV process testing mimics real-life scenarios to get ready to handle customers’ personal data securely.
To enable this service, Regula leverages its unique competencies in forensic examination, as well as IDV software and hardware development. The company personalizes NFC chips with fictitious persons’ data, which is recorded with the help of Regula’s document readers. Importantly, Regula generates all necessary certificate chains for every country in the list, signs the data using these certificates, and provides them to the customer for performing passive authentication. This approach fully imitates the scenario with real NFC chips in real IDs, which allows businesses to take advantage of lifelike document verification when testing their IDV systems.
Regula NFC TestKit is equipped with this functionality thanks to the fact that it is backed by the world’s most comprehensive identity document template database, which is exclusively owned and maintained by Regula. With more than 13,000 templates of IDs from 247 countries and territories, this database makes it possible to imitate nearly any identity document for testing purposes. And thanks to this asset, Regula is able to cover any geography a business may be interested in.
“Businesses currently strive to find suitable solutions to independently test the remote onboarding process of electronic documents, and until now, there have been no offerings on the market to address this gap. With our new service for complete imitation of real IDs, we enable organizations to conduct highly efficient testing to identify and prevent any potential issues prior to the launch of their IDV systems,” says Ihar Kliashchou, Chief Technology Officer at Regula.
Regula NFC TestKit service is provided exclusively for large enterprises that purchase the company’s software solutions. To learn more, contact Regula’s experts.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124863941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
